Interstitial Cystitis Drugs Market Size & Share, by Type [Nonsteroidal Anti-inflammatory Drugs, Tricyclic Antidepressants, Antihistamines, Pentosan Polysulfate Sodium (Elmiron); Dimethyl Sulfoxide (DMSO); Hyaluronic Acid (Cystistat)]; Route of Administration (Oral, Parenteral); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5257
  • Published Date: Sep 25, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024 - 2036

Interstitial Cystitis Drugs Market size is expected to cross USD 42 billion by the end of 2036, growing at a CAGR of 5% during the forecast period i.e., 2024 – 2036. In the year 2023, the industry size of interstitial cystitis drugs was USD 19 billion. The growth of this market can be attributed to the increasing product launches and drug approvals in the field of interstitial cystitis. The market players are highly intending on drug approvals and product launches by regulatory authorities that are expected to boost the market growth in the projected period. Such as in December 2019 the US Food and Drug Administration released a draft guidance detailing recommendations for the development of novel medications for the treatment of people with interstitial cystitis/bladder pain syndrome (IC/BPS).

Bladder pain and symptoms of the lower urinary tract are characteristics of interstitial cystitis. Although the precise etiology of the illness is unknown, many people, particularly women, are affected by it. Interstitial cystitis tends to be more common in women and is linked to a number of comorbid conditions, including endometriosis, fibromyalgia, and allergies. Current studies suggest that symptoms consistent with the diagnosis of interstitial cystitis occur in 2.7% to 6.5% of women in the United States.


Interstitial Cystitis Drugs Market
Get more information on this report: Request Free Sample PDF

Interstitial Cystitis Drug Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Awareness about Interstitial Cystitis – There is growing awareness about interstitial cystitis among patients, healthcare providers, and the general public. This further is leading to more diagnosis of interstitial cystitis and high demand for treatment options.
  • Rising Disposable Income – The rising disposable income in developed as well as in developing countries is leasing to increased spending on advanced healthcare facilities. The disposable income of people have grown from 24 million in 2021 to 28 million in 2022 in India.
  • Escalating Government Support – Governments in developed and emerging nations are highly supporting research and development activities in interstitial cystitis for developing new products. This is further contributing to create the favorable environment for the expansion of interstitial cystitis market.

Challenges

  • Lack of Approved Treatments – There are currently fewer FDA-approved drugs particularly for the treatment of interstitial cystitis. This has resulted in lack of effective treatment options for many patients. Therefore, due to this the growth of interstitial cystitis drugs market is expected to get affected in the upcoming future.
  • High Cost of Treatment
  • Availability of Competition

Interstitial Cystitis Drugs Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~5%

Base Year Market Size

~USD 19 billion

Forecast Year Market Size

~USD 42 billion

Regional Scope

  • North America (U.S. and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Interstitial Cystitis Drug Segmentation

Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

In terms of distribution channel, the hospital pharmacies segment is set to hold the largest market share of 40% by the end of 2036. Hospitals are primary setting for the diagnosis and treatment of interstitial cystitis. Patients with interstitial cystitis demand for prescription medications, that are typically dispensed by hospital pharmacies. Besides, hospitals pharmacies are also experienced in managing interstitial cystitis medications. They can provide patients with counselling on how to take their medication and monitor side effects.

Type [Nonsteroidal Anti-inflammatory Drugs, Tricyclic Antidepressants, Antihistamines, Pentosan Polysulfate Sodium (Elmiron), Dimethyl Sulfoxide (DMSO), Hyaluronic Acid (Cystistat)]

Based on the product, dimethyl sulfoxide segment in the interstitial cystitis drugs market is set to hold the highest CAGR during the assessment period. The segment gains since it is the most recent interstitial cystitis treatment and is thought to lessen swelling and pain associated with the condition. It could increase blood flow to the area being treated. Additionally, the US Food and Drug Administration (FDA) authorized the use of dimethyl sulfoxide (DMSO) on November 4, 2021, to treat interstitial cystitis. As a result, the demand for the medicine has skyrocketed.

Our in-depth analysis of the global market includes the following segments:

           Type

  • Nonsteroidal Anti-inflammatory Drugs
  •  Tricyclic Antidepressants
  • Antihistamines
  •  Pentosan Polysulfate Sodium (Elmiron)
  •  Dimethyl Sulfoxide (DMSO)
  • Hyaluronic Acid (Cystistat)

           Route of Administration

  • Oral
  • Parenteral

           Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Interstitial Cystitis Drug Landscape: Regional Synopsis

North America Market Forecasts

The interstitial cystitis drugs market in the North American is set to hold the highest growth of 33% during the anticipated period. The market is anticipated to grow as a result of a number of factors, including an increase in interstitial cystitis cases, increased research funding, improvements in interstitial cystitis diagnostic imaging, and widespread use of interstitial cystitis medications in the area. Some instances include interstitial cystitis (IC), which affected 5,894,905 people in the United States in 2018. In comparison, in the United States in 2020, the 8 million women.

APAC Market Statistics

The Asia Pacific interstitial cystitis drugs market is estimated to grow significantly during the projected timeframe. The growth of this market can be ascribed to the back of increasing population in the region. The population of the Asia Pacific region is growing rapidly, especially in India and China which further is leading to a high number of people getting affected by interstitial cystitis. Therefore, this is raising the demand for interstitial cystitis drugs in the Asia Pacific region. Besides, increasing urbanization activities in the APAC region are also considered to contribute to the market growth in this region. As escalating urbanization leads to advanced healthcare services and medication that also includes interstitial cystitis drugs.

Research Nester
Interstitial Cystitis Drugs Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Interstitial Cystitis Drug Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Johnson & Johnson
    •  Kyorin Pharmaceutical Co Ltd.
    • UCB Pharma
    • Bayer AG
    • Eli Lilly and Company
    • Lipella Pharmaceuticals
    • Seikagaku Corporation
    • Grünenthal

In the News

  • The Ministry of Health, Labor and Welfare granted Kyorin Pharmaceutical Co., Ltd. a license. marketing “Zymso 50% Intravenous Solution” for interstitial cystitis  in Japan. Kyorin Pharmaceutical Company Limited is a wholly owned subsidiary of KYORIN Holdings, Inc.
     
  • Kyorin Pharmaceutical Company Limited a wholly owned subsidiary of KYORIN Holdings, Inc., has launched the interstitial cystitis product "Zymso® Intravesical Solution 50%"

Author Credits:  Radhika Pawar


  • Report ID: 5257
  • Published Date: Sep 25, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of interstitial cystitis and growing innovation and product launches are some of the major factors anticipated to drive the growth of the interstitial cystitis drug market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024 – 2036.

The major players in the market are of Johnson & Johnson, Kyorin Pharmaceutical Co Ltd., UCB Pharma, Bayer AG, Eli Lilly and Company, Lipella Pharmaceuticals and others.

The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Interstitial Cystitis Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying